Low blood sugar is usually treated as a minor problem, fixed with juice or a snack. For people with hyperinsulinism, it is far more dangerous. Their bodies release insulin when they should not, pushing glucose down to levels that can cause seizures, brain injury and, in the worst cases, death. The condition, known as HI, is rare, and that rarity has kept treatment options thin for decades.
HI comes in two broad forms. Congenital HI shows up in newborns and young children and is caused by genetic defects in the cells that make insulin. It affects an estimated 1 in 25,000 to 1 in 50,000 live births, with much higher rates in some smaller, closely related populations. Diazoxide, approved about 40 years ago, is still the only FDA-approved drug for HI, and it often fails in children with the most severe genetic form. When medicine does not work, surgeons may remove part or nearly all of the pancreas, which can leave a child with diabetes later in life.Â
The second form is tumor HI. Here, a growth produces insulin or an insulin-like hormone called IGF-2. Insulinomas, small tumors of the pancreas, occur in roughly 1 to 4 people per million each year, and non-islet cell tumors that cause low blood sugar are rarer still. Surgery cures many insulinomas, but patients whose cancer has spread, or who are too sick for an operation, can end up in a hospital bed attached to a continuous intravenous glucose drip just to stay safe.Â
That last group explains why the field draws interest from drug developers. Small patient numbers mean small trials, regulators are often open to simpler study designs, and the medical need is obvious. The hard part is proving a drug works in a population this small and this varied, then paying for a launch with no revenue coming in.
One company has been living that challenge. Rezolute, Inc. (NASDAQ: RZLT) has a single drug, an antibody called ersodetug, that dampens the signal from excess insulin at the insulin receptor. In December 2025, its congenital HI study, sunRIZE, missed its main goal, and the stock fell almost 89% overnight.Â
Today brought a very different headline. The company said preliminary results from upLIFT, its Phase 3 study in tumor HI, met the primary goal. As of a November 5th data review, 13 of 16 patients had cut their IV glucose needs by at least half, and 12 stopped IV glucose altogether. The study needed only 9 responders, and no drug-related safety problems have been reported.Â
The same morning, the company priced an offering of 22,040,976 shares at $3.87 each, plus pre-funded warrants for up to 3,800,000 shares at $3.869, for gross proceeds of about $100 million. Frazier Life Sciences led the deal, which is expected to close November 16th. The company adivised that the money will be used to fund launch preparation for ersodetug, working capital and general corporate purposes.
Together, that is roughly 25.8 million new shares on top of about 104 million already outstanding, an increase of about 25%. Whether that trade makes sense depends on how much risk the data removes. The results are preliminary, three patients were still being treated at the data cut, and the study has no placebo group. The formal statistical results are due by mid-December, and the company expects to discuss next steps with the FDA in the first quarter of 2027.Â
The congenital program also looks healthier. In October, the FDA reviewed additional sunRIZE data and recommended the company file a Biologics License Application after a pre-BLA meeting. Management now plans to submit an application in 2027 for one or possibly both forms of HI.Â
That context changes how the raise reads. A specialist investor leading the round suggests belief in a real path to approval, not a rescue, and a launch needs a sales team and manufacturing well before approval arrives. The open questions are whether December’s final numbers hold up and whether the FDA agrees that a 16-patient, single-arm study is enough. If both go right, today’s dilution may look like the cost of reaching the market. If not, shareholders will have paid for preparation that came too early.
